Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Visus Merges with Tenpoint, Will Advance Brimochol Once-Daily Presbyopia Drop Candidate
Visus Therapeutics and Tenpoint Therapeutics announced Dec. 12 the completion of a merger, with plans to advance Visus’ Brimochol PF, a once-daily eye drop candidate for presbyopia. The combined co...
Acelyrin’s Izokibep Misses Endpoints in Phase IIb/III Uveitis Trial
Acelyrin reported Dec. 10 that izokibep, an inhibitor of interleukin-17A, missed its endpoints in a Phase IIb/III trial in non-infectious, non-anterior uveitis. The company said it would drop izoki...
NurExone Reports Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
NurExone Biologic, with offices in Canada and Israel, reported Dec. 6 findings of a preclinical study of its lead candidate, ExoPTEN, for repairing optic nerve damage. Researchers utilized a rodent...
Fall of Restasis Weighs on Dry Eye Revenue in 2024
Restasis continued to act as a brake on prescription dry eye pharmaceutical revenue in 2024 as its US sales kept plummeting. AbbVie reported that sales of the one-time blockbuster drug in the US fe...
Aflibercept Biosimilar Candidate from Celltrion Gains Positive CHMP Opinion
South Korea’s Celltrion announced Dec. 15 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued positive opinions recommending approval of three of i...
ViaLase Teams up with Moran Eye Center to Enhance Femto Laser Glaucoma Procedure
ViaLase of Aliso Viejo, California, reported Dec. 10 that it would partner with the John A. Moran Eye Center at the University of Utah to explore the effect of creating multiple channels in the tra...
SIFI Files for UK Approval of Akantior Drops for Acanthamoeba Keratitis
Italy’s SIFI reported Dec. 16 that it had filed a marketing authorization application with the UK’s Medicines and Healthcare Products Regulatory Agency for Akantior (polihexanide 0.08%) drops for t...
Nidek Launches NP-T Preloaded Toric IOL Injector Globally
Japanese ophthalmic company Nidek announced Dec. 2 that it had launched the NP-T preloaded toric intraocular lens (IOL) injection system globally. Previously, the injector had been available only i...
Nicox Reports First Sale of Zerviate in China by Partner Ocumension
France’s Nicox reported Dec. 4 that its partner Ocumension Therapeutics had made the first commercial sale of Zerviate (cetirizine ophthalmic solution) 0.24% in China. Zerviate is indicated for ocu...
Ophthalmic Company Revenue Up 6.3 Percent as Four Companies Report Record-High Quarters
Ophthalmic manufacturer revenue in Q3-2024 totaled $11.8 billion. Revenue increased 6.3 percent from the same quarter in 2023 and increased 0.8 percent from Q2-2024. The total includes Market Scope...
Ophthalmologists Report 5.5 Percent Increase in Q3-2024 Procedure Volume
US ophthalmologists reported that ophthalmic procedures increased 5.5 percent in Q3-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...
Asia-Pacific Markets and Lens-Based Procedures Drive Refractive Surgery
Economic conditions continue to be cited as the reason for flat or declining laser-vision correction (LVC)surgery rates in some markets in 2024. However, a shift in refractive surgery types and hig...
Past News Stories
Zeiss Gains US Approval for Next-Gen MEL 90 Excimer Laser
Carl Zeiss Meditec gained US FDA approval on Dec. 4 for its MEL 90 excimer laser, the next-generation iteration of its MEL 80 for LASIK surgery. The MEL 90’s US labeling is for correction of myopia...
Bausch + Lomb Acquires Elios Vision, Developer of Excimer Laser Trabeculostomy
Bausch + Lomb announced Dec. 11 that an affiliate had acquired Elios Vision, developer of the Elios excimer laser trabeculostomy procedure for glaucoma. No financial details were disclosed. Elios’ ...
Eyenovia Scraps Phase III Study of Low-Dose Atropine Candidate in Myopia
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Konan Medical Launches ObjectiveField Perimeter in the US
Konan Medical has launched its ObjectiveField visual field analyzer in the US. The ObjectiveField is an objective perimeter designed to detect visual field abnormalities using pupillary responses. ...
Select US FDA Approvals and Clearances in November 2024
The US FDA granted one clearance through the ophthalmic device division using the 510(k) pathway in November 2024, according to the agency’s database. Novoxel, a newcomer to ophthalmology but not m...
PDUFA Dates for Ophthalmic Drug Candidates
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
Topcon Weighing Takeover Bids from Private Equity Firms, Bloomberg Reports
Topcon is considering takeover bids from suitors including the private equity firms KKR & Co. and EQT AB, according to a report Dec. 10 from financial news outlet Bloomberg. The Tokyo-based ophthal...
NIH Joins Push to Fund Breakthroughs in Oculomics Diagnostic Tech
The National Institutes of Health (NIH) is joining the push to fund the development of technologies and biomarkers to diagnose systemic disease through the eye, a field known as oculomics. The NIH ...
US FDA Rejects sNDA for Izervay Seeking Every-Other-Month Dosing
Japan’s Astellas Pharma announced Nov. 19 that the US FDA had issued a complete response letter rejecting its supplemental new drug application (sNDA) for Izervay seeking to expand the drug’s label...
2025-2026 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million
Clearside Biomedical’s Asia-Pacific partner, Arctic Vision, announced Nov. 7 that it had licensed Chinese commercialization rights for ARVN001, marketed in the US as Xipere, to Santen Pharmaceutica...
Clinical Trial Updates for Ophthalmic Candidates, December 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.